Misplaced Pages

Dalbavancin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 19:12, 15 September 2010 editJonowen008 (talk | contribs)5 editsNo edit summary← Previous edit Latest revision as of 12:47, 11 January 2025 edit undoPreimage (talk | contribs)Extended confirmed users1,273 edits added Category:Chloroarenes using HotCat 
(120 intermediate revisions by 65 users not shown)
Line 1: Line 1:
{{Short description|Antibiotic used to treat MRSA}}
{{Use dmy dates|date=May 2022}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| IUPAC_name =
| Watchedfields = changed
| image = Dalbavancin.png
| verifiedrevid = 385028149
| CAS_number = 171500-79-1
| image = Dalbavancin_B0.svg
| ATC_prefix = J01
| alt =
| ATC_suffix = XA04

| PubChem = 16134410
<!-- Clinical data -->
| DrugBank =
| pronounce =
| C=88|H=100|Cl=2|N=10|O=28
| tradename = Dalvance, Xydalba, others
| molecular_weight = 1755.634 g/mol
| Drugs.com = {{drugs.com|monograph|dalbavancin-hydrochloride}}
| bioavailability =
| protein_bound = | MedlinePlus = a614036
| metabolism = | DailyMedID = Dalbavancin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| elimination_half-life =
| pregnancy_AU_comment =
| excretion =
| pregnancy_category=
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category=
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration = ] | routes_of_administration = ]
| class =
| ATC_prefix = J01
| ATC_suffix = XA04
| ATC_supplemental =

<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Summary Basis of Decision (SBD) for Xydalba | website=] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00413&lang=en | access-date=29 May 2022}}</ref><ref>{{cite web | title=Drug and medical device highlights 2018: Helping you maintain and improve your health | website=] | date=14 October 2020 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html | access-date=17 April 2024}}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Dalvance FDA label">{{cite web | title=Dalvance- dalbavancin injection, powder, for solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c | access-date=12 February 2022}}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Xydalba EPAR">{{cite web | title=Xydalba EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba | access-date=12 February 2022}}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life = {{Val|14.4|u=day}}<ref name="pmid38075413"/>
| duration_of_action =
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 171500-79-1
| PubChem = 16134627
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06219
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 23340937
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 808UI9MS5K
| KEGG_Ref =
| KEGG = D03640
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 82721
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 3301669
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =

<!-- Chemical and physical data -->
| IUPAC_name = 2-deoxy-1-O-carbamoyl}-6,11,34,40,44-pentahydroxy-42-(α-D-mannopyranosyloxy)-15-(methylamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahydro-1H,15H,34H-20,23:30,33-dietheno-3,18:35,48-bis(iminomethano) 4,8:10,14:25,28:43,47-tetramethenodioxadiazacyclooctacosino benzoxadiazacyclohexacosin-56-yl]-2--β-D-glucopyranuronic acid <ref name="EMA_assessment"/>
| C=88 | H=100 | Cl=2 | N=10 | O=28
| smiles = CC(C)CCCCCCCCC(=O)N1(((O1Oc2c3cc4cc2Oc5ccc(cc5Cl)(6C(=O)N(c7cc(cc(c7-c8cc(ccc8O)(C(=O)N6)NC(=O)4NC(=O)9c1cc(cc(c1Cl)O)Oc1ccc(cc1O)(C(=O)N(Cc1ccc(cc1)O3)C(=O)N9)NC)O1((((O1)CO)O)O)O)O)C(=O)NCCCN(C)C)O)C(=O)O)O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-23-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-24-18-41(30-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IZJRUXNZMRDQJI-SZUNQUCBSA-N
}} }}
'''Dalbavancin''' (], trade name '''Zeven''') is a novel second-generation ] ]. It belongs to the same class as ], the most widely-used and one of the few treatments available to patients infected with ] (MRSA).<ref></ref>


'''Dalbavancin''', sold under the brand names '''Dalvance''' in the US and '''Xydalba''' in the EU (both by AbbVie) among others, is a second-generation ] ] medication. It belongs to the same class as ], the most widely used and one of the treatments available to people infected with ] (MRSA).<ref>{{Cite web|url=https://www.drugs.com/nda/dalbavancin_041221.html|title=Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration|website=Drugs.com}}</ref>
It possesses in vitro activity against a variety of ] pathogens<ref name="pmid17362476">{{cite journal |author=Chen AY, Zervos MJ, Vazquez JA |title=Dalbavancin: a novel antimicrobial |journal=Int. J. Clin. Pract. |volume=61 |issue=5 |pages=853–63 |year=2007 |pmid=17362476 |doi=10.1111/j.1742-1241.2007.01318.x |pmc=1890846}}</ref><ref name="pmid18166524">{{cite journal |author=Das B, Sarkar C, Biswas R, Pandey S |title=Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens |journal=Pak J Pharm Sci |volume=21 |issue=1 |pages=78–88 |year=2008 |pmid=18166524 |doi=}}</ref> including ] and ].<ref></ref> It is a once-weekly, two-dose ] that ] acquired when it bought ] in 2005.<ref></ref>


Dalbavancin is a ] lipoglycopeptide that was designed to improve upon the natural ]s vancomycin and ].<ref>{{cite journal | vauthors = Scheinfeld N | title = Dalbavancin: a review for dermatologists | journal = Dermatology Online Journal | volume = 12 | issue = 4 | pages = 6 | date = May 2006 | doi = 10.5070/D30WN7D4Q9 | pmid = 17083861 }}</ref> It is derived from a complex of glycopeptide antibiotics, referred to as A-40926, that is produced by a new strain of Actinomadura. Dalbavancin has been referred to in the scientific literature by a series of names: MDL-63397, A-!-1, BI-397, VER-001.{{medcn|date=May 2022}} These different labels reflected where the research had been carried out: MDL representing Merrell-Dow-Lepetit, where the initial complex was discovered; BI referring to BioSearch Italia where Dalbavancin itself was first synthesized; VER referring to Versicor (which Biosearch Italia merged with to create Vicuron Pharmaceuticals).{{citation needed|date=May 2022}} The phase I, II and III clinical trials were carried out of by Vicuron and the initial NDA filed.{{citation needed|date=May 2022}} Vicuron was acquired by Pfizer in 2005, which decided to not further develop Dalbavancin at that time, subsequently selling the rights to Durata Therapeutics in 2009.{{citation needed|date=May 2022}}
On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.<ref>{{cite press release

| title = Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
It possesses '']'' activity against a variety of ] pathogens<ref name="pmid17362476">{{cite journal | vauthors = Chen AY, Zervos MJ, Vazquez JA | title = Dalbavancin: a novel antimicrobial | journal = International Journal of Clinical Practice | volume = 61 | issue = 5 | pages = 853–63 | date = May 2007 | pmid = 17362476 | pmc = 1890846 | doi = 10.1111/j.1742-1241.2007.01318.x }}</ref><ref name="pmid18166524">{{cite journal | vauthors = Das B, Sarkar C, Biswas R, Pandey S | title = Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens | journal = ] | volume = 21 | issue = 1 | pages = 78–87 | date = January 2008 | pmid = 18166524 }}</ref> including ] and ] (MRSE).<ref>{{Cite web|url=http://www.medscape.com/viewarticle/540712|title=Dalbavancin: A Novel Lipoglycopeptide Antibacterial|website=Medscape}}</ref> It is a once-weekly, two-dose ], the rights to which ] acquired when it bought ] in 2014.<ref name=Dec2007> December 2007</ref>

The U.S. ] (FDA) approved dalbavancin in May 2014, for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria such as ''Staphylococcus aureus'' including methicillin-susceptible and methicillin-resistant strains of '']'', in intravenous dosage form.<ref name="FDA PR" /><ref name="Drug Approval Package">{{cite web | title=Drug Approval Package: Dalvance (dalbavancin hydrochloride) Lyophilized Powder for Injection NDA #021883 | website=U.S. ] (FDA) | date=24 June 2014 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021883Orig1s000TOC.cfm | access-date=21 May 2022}}</ref><ref></ref>

==Medical uses==
Dalbavancin is considered a long-lasting antibiotic due to its prolonged half-life ({{Val|14.4|u=day}}), high protein binding capacity, and intense tissue penetration. It binds reversibly to plasma proteins at approximately 93%, allowing for sustained drug concentrations over time. Dalbavancin demonstrates good tissue distribution, reaching therapeutic levels in skin structures, ] (found in joints), and bone tissue within 24 hours after administration. The benefits of this long-lasting nature are less frequent dosing requirements while maintaining efficacy.<ref name="pmid38075413">{{cite journal |vauthors=Micheli G, Chiuchiarelli M, Taccari F, Fantoni M |title=The role of long-acting antibiotics in the clinical practice: a narrative review |journal=Infez Med |volume=31 |issue=4 |pages=449–465 |date=2023 |pmid=38075413 |pmc=10705857 |doi=10.53854/liim-3104-4 |url=}}</ref>

Dalbavancin is an antibiotic used to treat acute bacterial ]s (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant ''Staphylococcus aureus'' (MRSA). MRSA infections have become problematic in the community and in healthcare settings due to resistance to many available antibiotics.<ref>{{Cite web|url=https://www.cdc.gov/mrsa/index.html|title=MRSA &#124; CDC|date=5 February 2019|website=www.cdc.gov}}</ref> Because dalbavancin has demonstrated efficacy against MRSA and other microorganisms to treat serious or life-threatening infections, it was the first drug approved as a ] under the Generating Antibiotic Incentives Now (GAIN) act, which is part of the FDA Safety and Innovation Act.<ref name="rph">{{Cite web |url=http://www.pharmacist.com/dalbavancin-first-iv-antibiotic-acute-bacterial-skin-infections |title=Dalbavancin: First I.V. antibiotic for acute bacterial skin infections |access-date=3 November 2014 |archive-date=14 February 2018 |archive-url=https://web.archive.org/web/20180214142106/http://www.pharmacist.com/dalbavancin-first-iv-antibiotic-acute-bacterial-skin-infections |url-status=dead }}</ref>

It has strong activity against many Gram-positive bacteria, including methicillin-sensitive and methicillin-resistant ''Staphylococcus aureus'', ''Streptococcus pyogenes'', ''Streptococcus agalactiae'', ''Streptococcus anginosus'', ''Streptococcus intermedius'', and ''Streptococcus constellatus.''<ref name="Dalvance FDA label" /> Based on MIC data and other studies, dalbavancin is more potent and bactericidal and therefore requires lower concentrations than vancomycin against these organisms.<ref name="nih">{{cite journal | vauthors = Bennett JW, Lewis JS, Ellis MW | title = Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review | journal = Ther Clin Risk Manag | volume = 4 | issue = 1 | pages = 31–40 | date = February 2008 | pmid = 18728718 | pmc = 2503664 | doi = 10.2147/tcrm.s46 | doi-access = free }}</ref> Dalbavancin also shows ''in vitro'' activity against vancomycin-susceptible ''Enterococcus faecium'' and ''Enterococcus faecalis''.<ref name="Dalvance FDA label" /> Other Gram-positive organisms belonging to the ''Bacillus'' spp., ''Listeria'' spp., and ''Corynebacterium'' spp. may show ''in vitro'' susceptibility, and dalbavancin may exhibit activity against enterococci expressing the VanB or VanC phenotype of acquired resistance against vancomycin.<ref name="nih" /><ref name="fda">{{Cite web |url=https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf |title=FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting. NDA 21-883: Dalvance (Dalbavancin) for Injection. |website=] |access-date=16 December 2019 |archive-date=23 June 2017 |archive-url=https://web.archive.org/web/20170623024507/https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm390792.pdf |url-status=dead }}</ref> There is no clinically significant activity against Gram-negative bacteria.<ref name="nih" />

==Contraindications==
Hypersensitivity to dalbavancin can occur, causing issues such as skin reactions or anaphylaxis. Caution is advised for patients with known hypersensitivity to other glycopeptides. There is currently no data on cross-reactivity between dalbavancin and vancomycin.<ref name="Dalvance FDA label" />

==Side effects==
The most common adverse reactions encountered in Phase II and Phase III trials were nausea (5.5%), headache (4.7%), and diarrhea (4.4%), as well as rash (2.7%) and itchiness (2.1%). Other less frequent but serious adverse reactions included hematologic disorders, hepatotoxicity, '']'' ], ], infusion-related reactions including ], and anaphylactic shock.<ref name="Dalvance FDA label" /> In trials, dalbavancin was associated with higher rates of hemorrhagic events compared to comparator groups and should be a precaution in patients undergoing surgery or taking anticoagulants.<ref name="nih" /> Patients on dalbavancin also had post-baseline alanine aminotransferase (ALT) levels that were 3 times the upper normal limit, some even having elevations 10 times the upper normal limit; however, eight of the twelve dalbavancin-treated patients had comorbid conditions that could affect their ALT, compared to only one patient in the comparator group.<ref name="Dalvance FDA label" /> There is no evidence of ] associated with dalbavancin.<ref name="fda" />

===Drug interactions===
Clinical drug-drug interactions with dalbavancin have not been studied, and dalbavancin does not appear to interact with cytochrome P450 substrates, inhibitors, or inducers. It was found to have an ''in vitro'' synergistic interaction with the antimicrobial oxacillin, but the clinical significance of this interaction has yet to be established.<ref name="Dalvance FDA label" />

===Pregnancy and lactation===
The use of dalbavancin in pregnant women has not been studied sufficiently and should only occur when the potential benefit outweighs the potential risk to the fetus. Animal studies did not show embryo or fetal toxicity at doses that were 1.2 and 0.7 times the human dose. However, delayed fetal maturation was observed at a dose that was 3.5 times the human dose. While dalbavancin is excreted in rat milk, it is unknown if it is excreted in human milk. It should be used in nursing mothers only when the potential benefit exceeds the potential risk.<ref name="Dalvance FDA label" /> There is no evidence in animals of teratogenicity.<ref name="fda" />

==Production and composition==
Dalbavancin is manufactured by fermentation of a selected ] strain to generate the natural glycopeptide complex A-40926. This precursor is then selectively esterified at the carboxyl group of its sugar moiety, its peptidyl carboxyl group is amidated
and the ester of the N-acylaminoglucuronic acid carboxyl group is saponified.<ref name="patent_7119061"/> The outcome is a compound mixture of two closely related structural families — A and B — that can be further subdivided into a total of five subtypes (see table below).<ref name="EMA_assessment"></ref> At least ten different ''dalbavancin components'' have been described, of which the B<sub>0</sub> component makes up around 80–98 wt%.<ref name="patent_7119061">{{cite patent |country=US |number=7119061 |status=patent}}</ref>
{| class="wikitable"
|+ Dalbavancin homologs
|-
| colspan="3" | ]
|-
! Homolog!! Alkyl sidechain of ''N''-acylaminoglucuronic acid (R<sup>1</sup>) !! Amino-terminal substituent (R<sup>2</sup>)
|-
| A<sub>0</sub>|| CH(CH<sub>3</sub>)<sub>2</sub>|| H
|-
| A<sub>1</sub> || CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> || H
|-
| B<sub>0</sub> || CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub> || H
|-
| B<sub>1</sub> || CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> || H
|-
| B<sub>2</sub> || CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub> || CH<sub>3</sub>
|-
|}

==Mechanism of action==
Dalbavancin is a lipoglycopeptide belonging in the same glycopeptide class as vancomycin. Similar to other glycopeptides, dalbavancin exerts its bactericidal effect by disrupting cell wall biosynthesis. It binds to the D-alanyl-D-alanyl residue on growing peptidoglycan chains and prevents transpeptidation from occurring, preventing peptidoglycan elongation and cell wall formation. Dalbavancin also dimerizes and anchors itself in the lipophilic bacterial membrane, thereby increasing its stability in the target environment and its affinity for peptidoglycan.<ref name="nih" />

Antimicrobial activity correlates with the ratio of area under the concentration-time curve to minimum inhibitory concentration for ''Staphylococcus aureus''.<ref name="Dalvance FDA label" />

== Metabolism ==
When evaluated by in vitro studies, the ] of dalbavancin was minimally impacted by the human hepatic CYP450 system.<ref name=":0">{{cite journal | vauthors = Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS | title = Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) | journal = Therapeutics and Clinical Risk Management | volume = 12 | pages = 931–40 | date = June 2016 | pmid = 27354809 | pmc = 4907732 | doi = 10.2147/TCRM.S86330 | doi-access = free }}</ref> Further investigations with either inducers or inhibitors of this enzyme system demonstrated no changes in the elimination or clearance of dalbavancin, and the metabolism of model compounds of these CYP systems was not altered by the dalbavancin. Hydroxy-dalbavancin, a minor metabolite that has only been identified in urine, was also not changed in its formation or elimination with these enzyme models.<ref name=":0" /><ref>{{cite journal | vauthors = Buckwalter M, Dowell JA | title = Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide | journal = Journal of Clinical Pharmacology | volume = 45 | issue = 11 | pages = 1279–87 | date = November 2005 | pmid = 16239361 | doi = 10.1177/0091270005280378 | s2cid = 42875399 }}</ref>

==History==
Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the US ] (FDA) said more data were needed before approval.<ref name=Dec2007/> Pfizer withdrew its marketing applications to conduct another phase-III clinical trial in September 2008.<ref>{{cite press release
| title = Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
| publisher = ] | publisher = ]
| date = 2008-09-09 | date = 9 September 2008
| url = http://www.businesswire.com/news/pfizer/20080909005943/en | url = http://www.businesswire.com/news/pfizer/20080909005943/en
| accessdate = 2008-09-11 | access-date = 11 September 2008
| archive-date = 1 August 2019
}}</ref>Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.<ref>Scheinfeld NS. Dalbavancin: A review for dermatologists. Dermatology Online Journal 12 (4): 6. PMID 17083861</ref>
| archive-url = https://web.archive.org/web/20190801173337/https://www.businesswire.com/news/pfizer/20080909005943/en
| url-status = dead
}}</ref> ] acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ]s.<ref> Drug Discovery & Development - 5 October 2011.</ref> Preliminary results in 2012 were promising.<ref></ref>


About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin.<ref name="FDA PR">{{cite web | title=FDA approves Dalvance to treat skin infections | website=U.S. ] (FDA) | date=23 May 2014 | url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm | archive-url=https://web.archive.org/web/20140525203517/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm | archive-date=25 May 2014 | url-status=dead | access-date=12 February 2022}}</ref>
== References and notes ==
{{Reflist}}


In May 2014, dalbavancin was approved for medical use in the United States for ABSSSIs, including MRSA and ''Streptococcus pyogenes'' infections.<ref name="FDA PR" /><ref name="Drug Approval Package" />
{{Cell wall disruptive antibiotics}}


== References ==
]
{{Reflist}}


{{Other antibacterials}}
{{Portal bar | Medicine}}


]
{{antibiotic-stub}}
]
]